1
|
Wright SW, Farley KA, Han S, Knafels JD, Lee KL. In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833). ACS Med Chem Lett 2024; 15:540-545. [PMID: 38628800 PMCID: PMC11017396 DOI: 10.1021/acsmedchemlett.4c00036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Revised: 03/18/2024] [Accepted: 03/18/2024] [Indexed: 04/19/2024] Open
Abstract
In this paper, we disclose insights on the root causes of three structure-activity relationship (SAR) observations encountered in the discovery of the IRAK4 inhibitor Zimlovisertib (PF-06650833). The first is a nonlinear potency SAR encountered with the isoquinoline ether substituent, the second is a potency enhancement introduced by fluorine substitution on the lactam, and the third is a slight potency preference for all-syn (2S,3S,4S) stereochemistry in the fluorine-substituted lactam. We present new data that help to inform us of the origins of these unexpected SAR trends.
Collapse
Affiliation(s)
- Stephen W. Wright
- Medicine
Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Kathleen A. Farley
- Medicine
Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Seungil Han
- Medicine
Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - John D. Knafels
- Medicine
Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Katherine L. Lee
- Inflammation
and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
2
|
Wright SW. Synthesis of Deuterated Enaminones with High Isotopic Fidelity. ACS Med Chem Lett 2023; 14:1742-1745. [PMID: 38116410 PMCID: PMC10726438 DOI: 10.1021/acsmedchemlett.3c00395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 11/20/2023] [Accepted: 11/28/2023] [Indexed: 12/21/2023] Open
Abstract
The unexpected oxidation of nitrogenous heterocycles by aldehyde oxidase (AO) may be addressed by the substitution of deuterium for hydrogen adjacent to the heterocycle nitrogen atom. Enaminones are versatile intermediates in the synthesis of nitrogenous heterocycles. We report that heretofore inaccessible monodeuterated enaminones of the general structure RC(=O)CH=CDNMe2 may be synthesized from methyl ketones and DCO2Me with high isotopic fidelity and efficient utilization of deuterium.
Collapse
|
3
|
Wright SW, Choi C, Kawamata Y, Baran PS. Small Change, Big Impact: Reversal of Diastereoselection in Cuprate Conjugate Additions to α,β-Unsaturated Lactams and Identification of a Competing Mechanism. J Org Chem 2023; 88:4387-4396. [PMID: 36940148 DOI: 10.1021/acs.joc.2c02993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/21/2023]
Abstract
A seemingly minor change to a reactant is shown to cause a change in reaction mechanisms. Conjugate addition of organocopper reagents to bicyclic α,β-unsaturated lactams derived from pyroglutaminol is determined by the nature of the aminal group. Aminals derived from aldehydes give anti addition; those from ketones give syn addition. Divergence in diastereoselection occurs because the substrates react by different mechanisms, ultimately due to a small but significant difference in pyramidalization of the aminal nitrogen.
Collapse
Affiliation(s)
- Stephen W Wright
- Medicine Design, Pfizer Global Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Chulho Choi
- Medicine Design, Pfizer Global Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Yu Kawamata
- Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Phil S Baran
- Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
4
|
Choi C, Carlo AA, Cronin CN, Jing K, Kung DW, Liu J, Lombardo VM, Turco AR, Yin J, Yu A, Wright SW. Synthesis of Deuterated Heterocycles with Me 2NCD(OMe) 2 and Evaluation of the Products for Metabolism by Aldehyde Oxidase. ACS Med Chem Lett 2022; 13:250-256. [PMID: 35178182 PMCID: PMC8842100 DOI: 10.1021/acsmedchemlett.1c00634] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Accepted: 01/20/2022] [Indexed: 11/29/2022] Open
Abstract
The metabolic oxidation of drug-like small molecules by aldehyde oxidase (AO) has commonly been mitigated through the incorporation of deuterium at the oxidation site. We report that dimethylformamide dimethyl acetal and related compounds undergo rapid CH to CD isotopic exchange upon exposure to methanol-d and similar deuterated alcohols. This isotopic exchange process can be used to synthesize Me2NCD(OMe)2 and has significant implications for the use of Me2NCD(OMe)2 in the synthesis of specifically deuterium-labeled compounds. The application of Me2NCD(OMe)2 to the synthesis of various heterocycles that have been associated with AO metabolism is described, and we report the impact of deuteration on the rate of in vitro AO-mediated metabolism.
Collapse
Affiliation(s)
- Chulho Choi
- Medicine
Design, Pfizer Worldwide Research, Development
and Medical, Eastern Point Road, Groton, Connecticut 06340, United States,
| | - Anthony A. Carlo
- Structural
Biology and Protein Sciences, Pfizer Worldwide
Research, Development and Medical, La Jolla, California 92121, United States
| | - Ciarán N. Cronin
- Structural
Biology and Protein Sciences, Pfizer Worldwide
Research, Development and Medical, La Jolla, California 92121, United States
| | - Konghua Jing
- WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Daniel W. Kung
- Medicine
Design, Pfizer Worldwide Research, Development
and Medical, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jianhua Liu
- Structural
Biology and Protein Sciences, Pfizer Worldwide
Research, Development and Medical, La Jolla, California 92121, United States
| | - Vincent M. Lombardo
- Medicine
Design, Pfizer Worldwide Research, Development
and Medical, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Abigail R. Turco
- Medicine
Design, Pfizer Worldwide Research, Development
and Medical, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Juxing Yin
- WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Aijia Yu
- WuXi
AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Stephen W. Wright
- Medicine
Design, Pfizer Worldwide Research, Development
and Medical, Eastern Point Road, Groton, Connecticut 06340, United States,
| |
Collapse
|
5
|
|
6
|
Casimiro-Garcia A, Allais C, Brennan A, Choi C, Dower G, Farley KA, Fleming M, Flick A, Frisbie RK, Hall J, Hepworth D, Jones H, Knafels JD, Kortum S, Lovering FE, Mathias JP, Mohan S, Morgan PM, Parng C, Parris K, Pullen N, Schlerman F, Stansfield J, Strohbach JW, Vajdos FF, Vincent F, Wang H, Wang X, Webster R, Wright SW. Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1. J Med Chem 2021; 65:757-784. [PMID: 34967602 DOI: 10.1021/acs.jmedchem.1c01849] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A diaryl ketone series was identified as vanin-1 inhibitors from a high-throughput screening campaign. While this novel scaffold provided valuable probe 2 that was used to build target confidence, concerns over the ketone moiety led to the replacement of this group. The successful replacement of this moiety was achieved with pyrimidine carboxamides derived from cyclic secondary amines that were extensively characterized using biophysical and crystallographic methods as competitive inhibitors of vanin-1. Through optimization of potency and physicochemical and ADME properties, and guided by co-crystal structures with vanin-1, 3 was identified with a suitable profile for advancement into preclinical development.
Collapse
Affiliation(s)
- Agustin Casimiro-Garcia
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Christophe Allais
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Agnes Brennan
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Chulho Choi
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Gabriela Dower
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Kathleen A Farley
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Margaret Fleming
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Andrew Flick
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Richard K Frisbie
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Justin Hall
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - David Hepworth
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Hannah Jones
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - John D Knafels
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Steve Kortum
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Frank E Lovering
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - John P Mathias
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Sashi Mohan
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Paul M Morgan
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Chuenlei Parng
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Kevin Parris
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Nick Pullen
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Franklin Schlerman
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - John Stansfield
- Early Clinical Development Non-Clinical Statistics, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Joseph W Strohbach
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Felix F Vajdos
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Fabien Vincent
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Hong Wang
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Xiaolun Wang
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Robert Webster
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Stephen W Wright
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| |
Collapse
|
7
|
Petrova T, Nanda SK, Scudamore C, Wright SW, Rao VR, Cohen P. Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor. Lupus Sci Med 2021; 8:8/1/e000573. [PMID: 34836923 PMCID: PMC8628323 DOI: 10.1136/lupus-2021-000573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Accepted: 10/21/2021] [Indexed: 11/21/2022]
Abstract
Objective We have reported previously that the IRAK4 inhibitor PF06426779 given to ubiquitin-binding-defective ABIN1[D485N] mice at 6 weeks of age prevents the major facets of lupus that develop 10 weeks later. The present study was undertaken to investigate whether PF06426779 could reverse the lupus phenotype when administered to 13-week-old ABIN1[D485N] mice that had already developed symptoms of lupus. Methods Splenomegaly, the number of splenic neutrophils, TFH and Germinal Centre B (GCB) cells, serum levels of immunoglobulins, the extent of kidney, liver and lung pathology, and glomerular IgA and IgM were measured after feeding 13-week-old ABIN1[D485N] and wild-type mice for another 10 weeks with R&M3 diet with and without PF06426779 (4 g/kg). Results Following drug treatment, spleen size and weight, splenic neutrophil numbers, and serum IgA and glomerular IgA levels of ABIN1[D485N] mice returned to those seen in wild-type mice. The rise in splenic TFH and GCB numbers, the increase in kidney and liver pathology, and the concentrations of serum IgG1, IgG2A and IgE between 13 and 23 weeks were suppressed. There was no reduction in the level of anti-self double-stranded DNA, anti-self nuclear antigens or IgM during the drug treatment. Conclusions The results demonstrate the therapeutic potential of IRAK4 inhibitors for the treatment of lupus and raise the possibility of monitoring efficacy by measuring decreases in the serum levels of IgA. Our results support the view that there may be a closer connection between lupus and IgA nephropathy than realised previously.
Collapse
Affiliation(s)
- Tsvetana Petrova
- MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK
| | - Sambit K Nanda
- MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK
| | | | - Stephen W Wright
- Worldwide Medicinal Chemistry, Pfizer Inc, New York, New York, USA
| | - Vikram R Rao
- Inflammation and Immunology Research Unit, Pfizer Research Technology Center, Cambridge, Massachusetts, USA
| | - Philip Cohen
- MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK
| |
Collapse
|
8
|
Jones EV, Chen D, Wright SW, Trujillo JI, France S. Elucidation of a Sequential Iminium Ion Cascade Reaction Triggered by a Silica Gel-Promoted Aza-Peterson Reaction. J Org Chem 2020; 85:15660-15666. [PMID: 33226802 DOI: 10.1021/acs.joc.0c02102] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In a recent methodological study investigating the synthesis of N-alkoxyazomethine ylides, an unexpected aminal byproduct was generated during our attempt to isolate O-benzyl-N-((trimethylsilyl)methyl)hydroxylamine. After a strategic investigation, silica gel was discovered to be the cause of the byproduct formation. Through the mechanistic insight from control and trapping experiments, we propose the formation of a methaniminium ion via a novel aza-Peterson reaction, which ultimately triggers a sequential iminium ion cascade sequence. Herein, we discuss the elucidation of this cascade reaction mechanism and the constraints for the byproduct formation.
Collapse
Affiliation(s)
- Elizabeth V Jones
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
| | - Doris Chen
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
| | - Stephen W Wright
- Medicine Design, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - John I Trujillo
- Medicine Design, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Stefan France
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, United States.,Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
| |
Collapse
|
9
|
Gerstenberger BS, Ambler C, Arnold EP, Banker ME, Brown MF, Clark JD, Dermenci A, Dowty ME, Fensome A, Fish S, Hayward MM, Hegen M, Hollingshead BD, Knafels JD, Lin DW, Lin TH, Owen DR, Saiah E, Sharma R, Vajdos FF, Xing L, Yang X, Yang X, Wright SW. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem 2020; 63:13561-13577. [PMID: 32787094 DOI: 10.1021/acs.jmedchem.0c00948] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, respectively. On the basis of human genetic and emerging clinical data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clinical profile compared to currently approved JAK inhibitors. The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif. With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established. Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clinical candidate PF-06826647 (22).
Collapse
Affiliation(s)
| | | | - Eric P Arnold
- Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | - James D Clark
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | | | - Martin E Dowty
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Andrew Fensome
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Susan Fish
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | | | - Martin Hegen
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | | | | | - David W Lin
- Pfizer Inc., Groton, Connecticut 06340, United States
| | - Tsung H Lin
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Dafydd R Owen
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Eddine Saiah
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Raman Sharma
- Pfizer Inc., Groton, Connecticut 06340, United States
| | | | - Li Xing
- Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Xiaojing Yang
- Pfizer Inc., Groton, Connecticut 06340, United States
| | - Xin Yang
- Pfizer Inc., Groton, Connecticut 06340, United States
| | | |
Collapse
|
10
|
|
11
|
Kaewarpai T, Ekchariyawat P, Phunpang R, Wright SW, Dulsuk A, Moonmueangsan B, Morakot C, Thiansukhon E, Day NPJ, Lertmemongkolchai G, West TE, Chantratita N. Longitudinal profiling of plasma cytokines in melioidosis and their association with mortality: a prospective cohort study. Clin Microbiol Infect 2019; 26:783.e1-783.e8. [PMID: 31705997 DOI: 10.1016/j.cmi.2019.10.032] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 10/22/2019] [Accepted: 10/29/2019] [Indexed: 11/17/2022]
Abstract
OBJECTIVES To characterize plasma cytokine responses in melioidosis and analyse their association with mortality. METHODS A prospective longitudinal study was conducted in two hospitals in Northeast Thailand to enrol 161 individuals with melioidosis, plus 13 uninfected healthy individuals and 11 uninfected individuals with diabetes to act as controls. Blood was obtained from all individuals at enrolment (day 0), and at days 5, 12 and 28 from surviving melioidosis patients. Interferon-γ (IFN-γ), interleukin-1β (IL-1β), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, and tumour necrosis factor-α (TNF-α) were assayed in plasma. The association of each cytokine and its dynamics with 28-day mortality was determined. RESULTS Of the individuals with melioidosis, 131/161 (81%) were bacteraemic, and 68/161 (42%) died. On enrolment, median levels of IFN-γ, IL-6, IL-8, IL-10, IL-23 and TNF-α were higher in individuals with melioidosis compared with uninfected healthy individuals and all but IFN-γ were positively associated with 28-day mortality. Interleukin-8 provided the best discrimination of mortality (area under the receiver operating characteristic curve 0.78, 95% CI 0.71-0.85). Over time, non-survivors had increasing IL-6, IL-8 and IL-17A levels, in contrast to survivors. In joint modelling, temporal trajectories of IFN-γ, IL-6, IL-8, IL-10 and TNF-α predicted survival. CONCLUSIONS In a severely ill cohort of individuals with melioidosis, specific pro- and anti-inflammatory and T helper type 17 cytokines were associated with survival from melioidosis, at enrolment and over time. Persistent inflammation preceded death. These findings support further evaluation of these mediators as prognostic biomarkers and to guide targeted immunotherapeutic development for severe melioidosis.
Collapse
Affiliation(s)
- T Kaewarpai
- Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - P Ekchariyawat
- Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Department of Microbiology, Faculty of Public Health, Mahidol University, Bangkok, Thailand
| | - R Phunpang
- Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - S W Wright
- Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA
| | - A Dulsuk
- Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - B Moonmueangsan
- Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Department of Medicine, Mukdahan Hospital, Mukdahan, Thailand
| | - C Morakot
- Department of Medicine, Mukdahan Hospital, Mukdahan, Thailand
| | - E Thiansukhon
- Department of Medicine, Udon Thani Hospital, Udon Thani, Thailand
| | - N P J Day
- Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre of Tropical Medicine and Global Health, University of Oxford, Oxford, UK
| | - G Lertmemongkolchai
- Cellular and Molecular Immunology Unit, Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand
| | - T E West
- Division of Pulmonary, Critical Care & Sleep Medicine, Harborview Medical Center, University of Washington, Seattle, WA, USA; International Respiratory and Severe Illness Center, University of Washington, Seattle, WA, USA
| | - N Chantratita
- Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
| |
Collapse
|
12
|
Nanda SK, Petrova T, Marchesi F, Gierlinski M, Razsolkov M, Lee KL, Wright SW, Rao VR, Cohen P, Arthur JSC. Distinct signals and immune cells drive liver pathology and glomerulonephritis in ABIN1[D485N] mice. Life Sci Alliance 2019; 2:2/6/e201900533. [PMID: 31694920 PMCID: PMC6836709 DOI: 10.26508/lsa.201900533] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 10/24/2019] [Accepted: 10/24/2019] [Indexed: 01/01/2023] Open
Abstract
This article shows that liver and kidney damage in a lupus-prone mouse line occurs by different mechanisms and that only drugs targeting core components of signaling pathway, such as IRAK4, are able to suppress all facets of the disease. We report that TLR7, IL-6, and the adaptive immune system are essential for autoimmunity and glomerulonephritis but not for liver pathology in mice expressing the ubiquitin-binding–defective ABIN1[D485N] mutant. The blood and organs of ABIN1[D485N] mice have exceptionally high numbers of patrolling monocytes (pMo), which develop independently of IL-6 and the adaptive immune system. They are detectable in the blood months before autoimmunity and organ pathology are seen and may have diagnostic potential. The splenic pMo, inflammatory monocytes (iMo), and neutrophils of ABIN1[D485N] mice expressed high levels of mRNAs encoding proteins released during NETosis, which together with the high numbers of monocyte-derived dendritic cells (MoDCs) may drive the liver pathology in ABIN1[D485N] mice, and contribute to the pathology of other organs. The splenic iMo of ABIN1[D485N] mice displayed high expression of mRNAs encoding proteins controlling cell division and were actively dividing; this may underlie the increased pMo and MoDC numbers, which are derived from iMo. An orally active IRAK4 inhibitor suppressed all facets of the disease phenotype and prevented the increase in pMo numbers.
Collapse
Affiliation(s)
- Sambit Kumar Nanda
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK
| | - Tsvetana Petrova
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.,Division of Cell Signaling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK
| | - Francesco Marchesi
- School of Veterinary Medicine, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Marek Gierlinski
- Division of Computational Biology, School of Life Sciences, University of Dundee, Dundee, Scotland, UK
| | - Momchil Razsolkov
- Division of Cell Signaling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK
| | - Katherine L Lee
- Worldwide Medicinal Chemistry, Pfizer Inc, New York, NY, USA
| | | | - Vikram R Rao
- Inflammation and Immunology Research Unit, Pfizer Research, Cambridge, MA, USA
| | - Philip Cohen
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK
| | - J Simon C Arthur
- Division of Cell Signaling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK
| |
Collapse
|
13
|
Wright SW, Li B, Peng Z, Wei L, McInturff E, Place D, Damon DB, Singer RA. Improvements to Enable the Large Scale Synthesis of 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833). Org Process Res Dev 2018. [DOI: 10.1021/acs.oprd.8b00386] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Stephen W. Wright
- Medicine Design, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Bryan Li
- Chemical Research and Development, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Zhihui Peng
- Chemical Research and Development, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Lulin Wei
- Chemical Research and Development, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Emma McInturff
- Chemical Research and Development, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - David Place
- Chemical Research and Development, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - David B. Damon
- Chemical Research and Development, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert A. Singer
- Chemical Research and Development, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
14
|
Piotrowski DW, Futatsugi K, Casimiro-Garcia A, Wei L, Sammons MF, Herr M, Jiao W, Lavergne SY, Coffey SB, Wright SW, Song K, Loria PM, Banker ME, Petersen DN, Bauman J. Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists. J Med Chem 2018; 61:1086-1097. [PMID: 29300474 DOI: 10.1021/acs.jmedchem.7b01515] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset.
Collapse
Affiliation(s)
- David W Piotrowski
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Kentaro Futatsugi
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | | | - Liuqing Wei
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Matthew F Sammons
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Michael Herr
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Sophie Y Lavergne
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Steven B Coffey
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Stephen W Wright
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Kun Song
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Paula M Loria
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Mary Ellen Banker
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Donna N Petersen
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Jonathan Bauman
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| |
Collapse
|
15
|
Lee KL, Ambler CM, Anderson DR, Boscoe BP, Bree AG, Brodfuehrer JI, Chang JS, Choi C, Chung S, Curran KJ, Day JE, Dehnhardt CM, Dower K, Drozda SE, Frisbie RK, Gavrin LK, Goldberg JA, Han S, Hegen M, Hepworth D, Hope HR, Kamtekar S, Kilty IC, Lee A, Lin LL, Lovering FE, Lowe MD, Mathias JP, Morgan HM, Murphy EA, Papaioannou N, Patny A, Pierce BS, Rao VR, Saiah E, Samardjiev IJ, Samas BM, Shen MWH, Shin JH, Soutter HH, Strohbach JW, Symanowicz PT, Thomason JR, Trzupek JD, Vargas R, Vincent F, Yan J, Zapf CW, Wright SW. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem 2017; 60:5521-5542. [PMID: 28498658 DOI: 10.1021/acs.jmedchem.7b00231] [Citation(s) in RCA: 103] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays. The medicinal chemistry effort featured the judicious placement of lipophilicity, informed by co-crystal structures with IRAK4 and optimization of ADME properties to deliver clinical candidate PF-06650833 (compound 40). This compound displays a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Heidi M Morgan
- Worldwide Medicinal Chemistry, Pfizer Inc. , 1070 Science Center Drive, San Diego, California 92121, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Jiangli Yan
- Worldwide Medicinal Chemistry, Pfizer Inc. , 1070 Science Center Drive, San Diego, California 92121, United States
| | | | | |
Collapse
|
16
|
Kiziroglou ME, Boyle DE, Wright SW, Yeatman EM. Acoustic power delivery to pipeline monitoring wireless sensors. Ultrasonics 2017; 77:54-60. [PMID: 28183067 DOI: 10.1016/j.ultras.2017.01.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 01/18/2017] [Accepted: 01/19/2017] [Indexed: 06/06/2023]
Abstract
The use of energy harvesting for powering wireless sensors is made more challenging in most applications by the requirement for customization to each specific application environment because of specificities of the available energy form, such as precise location, direction and motion frequency, as well as the temporal variation and unpredictability of the energy source. Wireless power transfer from dedicated sources can overcome these difficulties, and in this work, the use of targeted ultrasonic power transfer as a possible method for remote powering of sensor nodes is investigated. A powering system for pipeline monitoring sensors is described and studied experimentally, with a pair of identical, non-inertial piezoelectric transducers used at the transmitter and receiver. Power transmission of 18mW (Root-Mean-Square) through 1m of a118mm diameter cast iron pipe, with 8mm wall thickness is demonstrated. By analysis of the delay between transmission and reception, including reflections from the pipeline edges, a transmission speed of 1000m/s is observed, corresponding to the phase velocity of the L(0,1) axial and F(1,1) radial modes of the pipe structure. A reduction of power delivery with water-filling is observed, yet over 4mW of delivered power through a fully-filled pipe is demonstrated. The transmitted power and voltage levels exceed the requirements for efficient power management, including rectification at cold-starting conditions, and for the operation of low-power sensor nodes. The proposed powering technique may allow the implementation of energy autonomous wireless sensor systems for monitoring industrial and network pipeline infrastructure.
Collapse
Affiliation(s)
- M E Kiziroglou
- Department of Electrical and Electronic Engineering, Imperial College London, London SW7 2AZ, United Kingdom.
| | - D E Boyle
- Department of Electrical and Electronic Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| | - S W Wright
- Department of Electrical and Electronic Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| | - E M Yeatman
- Department of Electrical and Electronic Engineering, Imperial College London, London SW7 2AZ, United Kingdom
| |
Collapse
|
17
|
Affiliation(s)
- Chulho Choi
- Medicinal Chemistry, Medicine Design, Pfizer WorldWide R&D, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Philippe Nuhant
- Medicinal Chemistry, Medicine Design, Pfizer WorldWide R&D, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - James J. Mousseau
- Medicinal Chemistry, Medicine Design, Pfizer WorldWide R&D, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Xiaojing Yang
- Medicinal Chemistry, Medicine Design, Pfizer WorldWide R&D, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Brian S. Gerstenberger
- Medicinal Chemistry, Medicine Design, Pfizer WorldWide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Jessica M. Williams
- Kutztown University of Pennsylvania, 15200 Kutztown Road, Kutztown, Pennsylvania 19530, United States
| | - Stephen W. Wright
- Medicinal Chemistry, Medicine Design, Pfizer WorldWide R&D, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
18
|
Houghton MJ, Huck CJ, Wright SW, Collum DB. Lithium Enolates Derived from Pyroglutaminol: Mechanism and Stereoselectivity of an Azaaldol Addition. J Am Chem Soc 2016; 138:10276-83. [PMID: 27500546 PMCID: PMC5240537 DOI: 10.1021/jacs.6b05481] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
A lithium enolate derived from an acetonide-protected pyroglutaminol undergoes a highly selective azaaldol addition with (E)-N-phenyl-1-[2-(trifluoromethyl)phenyl]methanimine. The selectivity is sensitive to tetrahydrofuran (THF) concentration, temperature, and the presence of excess lithium diisopropylamide base. Rate studies show that the observable tetrasolvated dimeric enolate undergoes reversible deaggregation, with the reaction proceeding via a disolvated-monomer-based transition structure. Limited stereochemical erosion stems from the intervention of a trisolvated-monomer-based pathway, which is suppressed at low THF concentrations and elevated temperature. Endofacial selectivity observed with excess lithium diisopropylamide (LDA) is traced to an intermediate dianion formed by subsequent lithiation of the monomeric azaaldol adduct, which is characterized as both a dilithio form and a trilithio dianion-LDA mixed aggregate.
Collapse
Affiliation(s)
- Michael J. Houghton
- Department of Chemistry and Chemical Biology Baker Laboratory, Cornell University Ithaca, New York 14853–1301
| | - Christopher J. Huck
- Department of Chemistry and Chemical Biology Baker Laboratory, Cornell University Ithaca, New York 14853–1301
| | - Stephen W. Wright
- Worldwide Medicinal Chemistry, Pfizer Global Research and Development, 445 Eastern Point Road, Groton, CT 06340
| | - David B. Collum
- Department of Chemistry and Chemical Biology Baker Laboratory, Cornell University Ithaca, New York 14853–1301
| |
Collapse
|
19
|
Houghton MJ, Biok NA, Huck CJ, Algera RF, Keresztes I, Wright SW, Collum DB. Lithium Enolates Derived from Pyroglutaminol: Aggregation, Solvation, and Atropisomerism. J Org Chem 2016; 81:4149-57. [PMID: 27035057 PMCID: PMC5245164 DOI: 10.1021/acs.joc.6b00459] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Lithium enolates derived from protected pyroglutaminols were characterized by using (6)Li, (13)C, and (19)F NMR spectroscopies in conjunction with the method of continuous variations. Mixtures of tetrasolvated dimers and tetrasolvated tetramers in different proportions depend on the steric demands of the hemiaminal protecting group, tetrahydrofuran concentration, and the presence or absence of an α-fluoro moiety. The high steric demands of the substituted bicyclo[3.3.0] ring system promote dimers to an unusual extent and allow solvents and atropisomers in cubic tetramers to be observed in the slow-exchange limit. Pyridine used as a (6)Li chemical shift reagent proved useful in assigning solvation numbers.
Collapse
Affiliation(s)
- Michael J. Houghton
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853–1301
| | - Naomi A. Biok
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853–1301
| | - Christopher J. Huck
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853–1301
| | - Russell F. Algera
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853–1301
| | - Ivan Keresztes
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853–1301
| | - Stephen W. Wright
- Worldwide Medicinal Chemistry, Pfizer Global Research and Development, 445 Eastern Point Road, Groton, CT 06340
| | - David B. Collum
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853–1301
| |
Collapse
|
20
|
Wright SW, Choi C, Chung S, Boscoe BP, Drozda SE, Mousseau JJ, Trzupek JD. Reversal of Diastereoselection in the Conjugate Addition of Cuprates to Unsaturated Lactams. Org Lett 2015; 17:5204-7. [DOI: 10.1021/acs.orglett.5b02533] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Stephen W. Wright
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Chulho Choi
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Seungwon Chung
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Brian P. Boscoe
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Susan E. Drozda
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - James J. Mousseau
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States
| | - John D. Trzupek
- Inflammation & Immunology Research, Pfizer Global Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
21
|
Affiliation(s)
| | - Neal Sach
- Oncology
Chemistry, Pfizer Global Research and Development, 10770 Science Center Drive, La Jolla, California 92121, United States
| | | | | | | | | | | |
Collapse
|
22
|
Wu J, Shin J, Williams CMM, Geoghegan KF, Wright SW, Limburg DC, Sahasrabudhe P, Bonin PD, Lefker BA, Ramsey SJ. Correction: Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins. Med Chem Commun 2015. [DOI: 10.1039/c4md90044h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Correction for ‘Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins’ by Jiang Wu et al., Med. Chem. Commun., 2014, 5, 1871–1878.
Collapse
Affiliation(s)
- Jiang Wu
- Structural Biology and Biophysics
- Worldwide Medicinal Chemistry
- Pfizer
- Groton
- USA
| | - Julia Shin
- Inflammation and Remodeling Research Unit
- Pfizer
- Cambridge
- USA
| | | | - Kieran F. Geoghegan
- Structural Biology and Biophysics
- Worldwide Medicinal Chemistry
- Pfizer
- Groton
- USA
| | | | | | - Parag Sahasrabudhe
- Structural Biology and Biophysics
- Worldwide Medicinal Chemistry
- Pfizer
- Groton
- USA
| | | | | | | |
Collapse
|
23
|
Wu J, Shin J, Williams CMM, Geoghegan KF, Wright SW, Limburg DC, Sahasrabudhe P, Bonin PD, Lefker BA, Ramsey SJ. Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins. Med Chem Commun 2014. [DOI: 10.1039/c4md00259h] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Selectivity of a PFI-1 based BET bromodomain probe was demonstrated using affinity capture in nuclear extracts from human cells.
Collapse
Affiliation(s)
- Jiang Wu
- Structural Biology and Biophysics
- Worldwide Medicinal Chemistry
- Groton
- USA
| | - Julia Shin
- Inflammation and Remodeling Research Unit
- Cambridge
- USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Sammons M, Jennings SM, Herr M, Hulford CA, Wei L, Hallissey JF, Kiser EJ, Wright SW, Piotrowski DW. Synthesis of a cis 2,5-Disubstituted Morpholine by De-epimerization: Application to the Multigram Scale Synthesis of a Mineralocorticoid Antagonist. Org Process Res Dev 2013. [DOI: 10.1021/op400101p] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Matthew Sammons
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Sandra M. Jennings
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Michael Herr
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Catherine A. Hulford
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - James F. Hallissey
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - E. Jason Kiser
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Stephen W. Wright
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| |
Collapse
|
25
|
Futatsugi K, Mascitti V, Guimarães CR, Morishita N, Cai C, DeNinno MP, Gao H, Hamilton MD, Hank R, Harris AR, Kung DW, Lavergne SY, Lefker BA, Lopaze MG, McClure KF, Munchhof MJ, Preville C, Robinson RP, Wright SW, Bonin PD, Cornelius P, Chen Y, Kalgutkar AS. From partial to full agonism: Identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor. Bioorg Med Chem Lett 2013. [DOI: 10.1016/j.bmcl.2012.10.119] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
26
|
|
27
|
Filipski KJ, Bian J, Ebner DC, Lee EC, Li JC, Sammons MF, Wright SW, Stevens BD, Didiuk MT, Tu M, Perreault C, Brown J, Atkinson K, Tan B, Salatto CT, Litchfield J, Pfefferkorn JA, Guzman-Perez A. A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity. Bioorg Med Chem Lett 2012; 22:415-20. [DOI: 10.1016/j.bmcl.2011.10.113] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Revised: 10/25/2011] [Accepted: 10/31/2011] [Indexed: 11/25/2022]
|
28
|
|
29
|
|
30
|
|
31
|
Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD, Lillquist JS, Liu S, McClure LD, McPherson RK, Olson TV, Orena SJ, Parker JC, Rocke BN, Soeller WC, Soglia CB, Treadway JL, Vanvolkenburg MA, Zhao Z, Cox ED. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Bioorg Med Chem Lett 2007; 17:5638-42. [PMID: 17822893 DOI: 10.1016/j.bmcl.2007.07.081] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2007] [Revised: 07/20/2007] [Accepted: 07/23/2007] [Indexed: 11/21/2022]
Abstract
A series of pyrrolidine based inhibitors of dipeptidyl peptidase IV were developed from a high throughput screening hit for the treatment of type 2 diabetes. Potency, selectivity, and pharmacokinetic properties were optimized resulting in the identification of a pre-clinical candidate for further profiling.
Collapse
Affiliation(s)
- Stephen W Wright
- Pfizer Global Research and Development, Cardiovascular and Metabolic Diseases, MS 8220-3141, Eastern Point Road, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Heteroaromatic thiols may be oxidized to the sulfonyl chloride at low temperature (-25 degrees C) by using 3.3 equiv of aqueous sodium hypochlorite. The reaction is rapid, avoids the use of chlorine gas, and succeeds with substrates that have previously been found to afford little or none of the sulfonamide product with other procedures. The method allows the preparation of the sulfonyl fluorides, which are stable enough to be purified and stored, making them potentially useful monomers in parallel chemistry efforts.
Collapse
Affiliation(s)
- Stephen W Wright
- Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
| | | |
Collapse
|
33
|
Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD, Lillquist JS, McClure LD, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soeller WC, Soglia CB, Treadway JL, VanVolkenburg MA, Wang H, Wilder DC, Olson TV. cis-2,5-Dicyanopyrrolidine Inhibitors of Dipeptidyl Peptidase IV: Synthesis and in Vitro, in Vivo, and X-ray Crystallographic Characterization. J Med Chem 2006; 49:3068-76. [PMID: 16722626 DOI: 10.1021/jm0600085] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Inhibitors of the glucagon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be effective treatments for type 2 diabetes in animal models and in human subjects. A novel series of cis-2,5-dicyanopyrrolidine alpha-amino amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. 1-({[1-(Hydroxymethyl)cyclopentyl]amino}acetyl)pyrrolidine-2,5-cis-dicarbonitrile (1c) is an achiral, slow-binding (time-dependent) inhibitor of DPP-IV that is selective for DPP-IV over other DPP isozymes and proline specific serine proteases, and which has oral bioavailability in preclinical species and in vivo efficacy in animal models. The mode of binding of the cis-2,5-dicyanopyrrolidine moiety was determined by X-ray crystallography. The hydrochloride salt of 1c was further profiled for development as a potential new treatment for type 2 diabetes.
Collapse
Affiliation(s)
- Stephen W Wright
- Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Heteroaromatic thiols may be oxidized to the sulfonyl chloride at low temperature (-25 degrees C) by using 3.3 equiv of aqueous sodium hypochlorite. The reaction is rapid, avoids the use of chlorine gas, and succeeds with substrates that have previously been found to afford little or none of the sulfonamide product with other procedures. The method allows the preparation of the sulfonyl fluorides, which are stable enough to be purified and stored, making them potentially useful monomers in parallel chemistry efforts.
Collapse
Affiliation(s)
- Stephen W Wright
- Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
| | | |
Collapse
|
35
|
Wright SW, Rath VL, Genereux PE, Hageman DL, Levy CB, McClure LD, McCoid SC, McPherson RK, Schelhorn TM, Wilder DE, Zavadoski WJ, Gibbs EM, Treadway JL. 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Bioorg Med Chem Lett 2005; 15:459-65. [PMID: 15603973 DOI: 10.1016/j.bmcl.2004.10.048] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2004] [Revised: 10/13/2004] [Accepted: 10/15/2004] [Indexed: 11/23/2022]
Abstract
The synthesis, in vitro, and in vivo biological characterization of a series of achiral 5-chloroindoloyl glycine amide inhibitors of human liver glycogen phosphorylase A are described. Improved potency over previously reported compounds in cellular and in vivo assays was observed. The allosteric binding site of these compounds was shown by X-ray crystallography to be the same as that reported previously for 5-chloroindoloyl norstatine amides.
Collapse
Affiliation(s)
- Stephen W Wright
- Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Wright SW, Carlo AA, Danley DE, Hageman DL, Karam GA, Mansour MN, McClure LD, Pandit J, Schulte GK, Treadway JL, Wang IK, Bauer PH. 3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorg Med Chem Lett 2003; 13:2055-8. [PMID: 12781194 DOI: 10.1016/s0960-894x(03)00310-x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
3-(2-Carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid (MDL-29951), an antagonist of the glycine site of the NMDA receptor, has been found to be an allosteric inhibitor of the enzyme fructose 1,6-bisphosphatase. The compound binds at the AMP regulatory site by X-ray crystallography. This represents a new approach to inhibition of fructose 1,6-bisphosphatase and serves as a lead for further drug design.
Collapse
Affiliation(s)
- Stephen W Wright
- Pfizer Central Research, Eastern Point Road, Box 8220-3141, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Wright SW, Carlo AA, Carty MD, Danley DE, Hageman DL, Karam GA, Levy CB, Mansour MN, Mathiowetz AM, McClure LD, Nestor NB, McPherson RK, Pandit J, Pustilnik LR, Schulte GK, Soeller WC, Treadway JL, Wang IK, Bauer PH. Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. J Med Chem 2002; 45:3865-77. [PMID: 12190310 DOI: 10.1021/jm010496a] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The synthesis and in vitro structure-activity relationships (SAR) of a novel series of anilinoquinazolines as allosteric inhibitors of fructose-1,6-bisphosphatase (F16Bpase) are reported. The compounds have a different SAR as inhibitors of F16Bpase than anilinoquinazolines previously reported. Selective inhibition of F16Bpase can be attained through the addition of appropriate polar functional groups at the quinazoline 2-position, thus separating the F16Bpase inhibitory activity from the epidermal growth factor receptor tyrosine kinase inhibitory activity previously observed with similar structures. The compounds have been found to bind at a symmetry-repeated novel allosteric site at the subunit interface of the enzyme. Inhibition is brought about by binding to a loop comprised of residues 52-72, preventing the necessary participation of these residues in the assembly of the catalytic site. Mutagenesis studies have identified the key amino acid residues in the loop that are required for inhibitor recognition and binding.
Collapse
Affiliation(s)
- Stephen W Wright
- Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
|
39
|
|
40
|
|
41
|
|
42
|
Corey EJ, Wright SW, Matsuda SPT. Stereochemistry and mechanism of the biosynthesis of leukotriene A4 from 5(S)-hydroperoxy-6(E),8,11,14(Z)-eicosatetraenoic acid. Evidence for an organoiron intermediate. J Am Chem Soc 2002. [DOI: 10.1021/ja00186a046] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
|
44
|
Wright SW, Hageman DL, McClure LD, Carlo AA, Treadway JL, Mathiowetz AM, Withka JM, Bauer PH. Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines. Bioorg Med Chem Lett 2001; 11:17-21. [PMID: 11140724 DOI: 10.1016/s0960-894x(00)00586-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Anilinoquinazolines currently of interest as inhibitors of tyrosine kinases have been found to be allosteric inhibitors of the enzyme fructose 1,6-bisphosphatase. These represent a new approach to inhibition of F16BPase and serve as leads for further drug design. Enzyme inhibition is achieved by binding at an unidentified allosteric site.
Collapse
Affiliation(s)
- S W Wright
- Pfizer Central Research, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
The practice of emergency medicine in Ukraine is markedly different from the practice in North America. The emergency physician counterpart in Ukraine attends 6 years of medical school then 18 months of prehospital physician training at an EMS base station. Once trained, prehospital physicians work 160 hours/month in 24-hour shifts at the base station as part of a physician-nurse team which answers ambulance requests. Most patients are seen and treated on site of the ambulance call. Patients are transported to the hospital only 20% of the time. Prehospital physicians can expect to earn $35 to $65 per month. Nearly all prehospital physicians are government employees. Since becoming an independent democratic republic, Ukraine's turbulent economy has negatively affected health care. Deaths from infectious diseases, including vaccine-preventable illnesses are 10-fold to that of Western countries. A 90% income tax discourages the private practice of medicine. Medical care is provided free of charge, however, if a patient wants a higher standard of care, they may have to pay an attending physician up to $200. Most medications used to treat emergencies are free, but if thrombolytics are required, the patient will have to pay for them before they are administered. Budgetary constraints limit equipment and technology. The disparity between urban and rural resources is striking as even the most basic equipment is antiquated and in need of repair. Despite the economic challenges facing Ukranian physicians, they are enthusiastic about the care and services they provide. EMS is well organized and offers services not seen in the United States. Prehospital physicians in Ukraine are viewed as an integral part of the health care system by their hospital-based colleagues.
Collapse
Affiliation(s)
- S W Wright
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
| | | | | | | |
Collapse
|
46
|
Wright SW. A CONVENIENT PREPARATION OF METHYL 4-(2-AMINOETHYL)BENZOATE. ORG PREP PROCED INT 2000. [DOI: 10.1080/00304940009355938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
47
|
Abstract
OBJECTIVES The purpose of this study was to investigate patron attitudes toward a walk through a metal detector that was used for universal weapon screening in a pediatric emergency department. Additionally, we conducted a telephone survey to determine the nationwide prevalence of metal detectors in pediatric emergency departments. METHODS A convenience sample of family and acquaintances of patients seen in the pediatric emergency department was selected, and members were interviewed using scripted questions. Members of the National Association of Children's Hospitals and Related Institutions were interviewed for the nationwide survey. RESULTS The vast majority of patrons responded favorably to the presence of the arch-style walk through a metal detector. The metal detector was felt to be appropriate in a pediatric emergency department by a large majority of patrons and was protective for both patrons and employees. Handbag searches were felt to be an invasion of privacy by 14%. Nationwide, the prevalence of arch-style metal detectors for security purposes in pediatric emergency departments was only 6%. CONCLUSIONS The public has a strong perception that a metal detector protects both patrons and employees in a pediatric emergency department. Fear that patrons will be disturbed or that the presence of a metal detector will reflect negatively upon the institution appear to be unfounded. Nationwide use of metal detectors in pediatric emergency departments remains uncommon but is apparently increasing.
Collapse
Affiliation(s)
- E A Mattox
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | | | | |
Collapse
|
48
|
Abstract
The purpose of this study was to describe resistance patterns of infecting organisms and determine risk factors for multidrug resistance in patients with urinary tract infections. Retrospective case series of 435 patients age > or =16 with urinary tract infection. Multidrug resistance was defined as resistance to > or = two classes of antibiotics. Demographic, historical, and microbiological data were collected. Univariate analysis and multivariate logistic regression were used to determine risk factors for multidrug resistance. Multidrug resistance was seen in 37% of isolates. Univariate analysis revealed numerous associations with resistance. Multivariate analysis found three independent factors associated with multidrug resistance: urinary catheter use (odds ratio [OR] 2.6, 95% confidence interval [CI] 1.4 to 4.8), age > or = 65 years (OR 3.0, 95% CI 1.7 to 5.4) and antibiotic use (OR 4.6, 95% CI 2.8 to 7.5). Diabetes was also a risk factor when patients with urinary catheters were excluded (OR 2.4, 95% CI 1.1 to 5.3). Resistance was seen in all groups of patients, but was particularly common in older patients and those who used a urinary catheter. Antibiotic use was highly associated with multidrug resistance.
Collapse
Affiliation(s)
- S W Wright
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | | | | | | |
Collapse
|
49
|
Abstract
OBJECTIVE A large majority of urinary tract infections are caused by coliform organisms. Trimethoprim-sulfamethoxazole (TMP-SMX) resistance among uropathogens is increasing in many areas. The objective of this study was to determine risk factors for TMP-SMX-resistant coliforms in patients with urinary tract infections. DESIGN Retrospective case-control study. SETTING Emergency department of a tertiary care university hospital. PATIENTS We studied 448 emergency department patients aged 14 years or older with a urinary tract infection caused by a coliform organism. Cases consisted of all patients with a culture-documented urinary tract infection caused by a TMP-SMX-resistant coliform, while control patients were those with a TMP-SMX-sensitive organism. MEASUREMENTS AND MAIN RESULTS A univariate analysis of clinical variables associated with TMP-SMX resistance was performed. Multiple logistic regression was performed to determine independent predictors of TMP-SMX resistance. Resistance to TMP-SMX was seen in 15% of isolates. Numerous variables were associated with TMP-SMX resistance on the univariate screen. Independent predictors of resistance were diabetes (odds ratio [OR] 3.1; 95% confidence interval [CI] 1.2, 8.4), recent hospitalization (OR 2.5; 95% CI 1.1, 5.7), current use of antibiotics (OR 4.5; 95% CI 2.0, 10.2), and recent use of TMP-SMX (OR 5.1; 95% CI 2.2, 11.5). When those with recent hospitalization were excluded from analysis, independent predictors were current use of any antibiotic (OR 3.5; 95% CI 1.4, 8. 4) and recent use of TMP-SMX (OR 5.9; 95% CI 2.4, 14.3). CONCLUSIONS Coliforms resistant to TMP-SMX are common in our emergency department. Diabetes, recent hospitalization, and the use of antibiotics, particularly the use of TMP-SMX, are independent risk factors for TMP-SMX resistance. Clinicians should consider these findings when deciding on antimicrobial therapy for patients with urinary tract infections.
Collapse
Affiliation(s)
- S W Wright
- Department of Emergency Medicine, Vanderbilt University Medical Center,Nashville, Tennessee, USA
| | | | | |
Collapse
|
50
|
Abstract
We tried to measure anxiety levels in emergency medical service (EMS) providers to determine the effects of (1) having had a violent encounter during a shift and (2) different shift schedules, conducting a prospective observational study over 3 months in an urban EMS system setting. A convenience sample of 23 EMTs and 40 EMT-Ps was observed. Anxiety levels were measured using the Spielberger State-Trait Anxiety Inventory. A total of 99 inventories were completed by 63 EMS providers. The mean state (32.6+/-8) and trait (31.7+/-7.1) scores were less than normative scores (35.7+/-10.4 and 34.9+/-9.2 respectively) for working adult males (P = .004 and .007, respectively). Paramedics had lower anxiety scores than basic EMTs (P = .015 and .039) and years of experience also decreased anxiety scores (P < .0001). There was no significant difference in state scores between those EMS providers who had encountered violence during the preceding 12 hours and those providers who had not. Comparisons of state scores of providers assessed at hour 12 of a 12 hour shift, hour 12 of a 24 hour shift, and hour 24 of a 24 hour shift failed to show any significant differences. Although the working environment of the EMS provider contains numerous stressors and uncertainties, this population of providers were no more anxious than the general working public. Advanced training and years of experience decreased anxiety. Violent encounters during a shift did not appear to affect anxiety levels. There was no difference in anxiety levels in providers who worked 12 and 24 hour shifts.
Collapse
Affiliation(s)
- E F Mock
- Department of Emergency Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | | | | | | | | |
Collapse
|